金沙(8888js-官方JS认证)-Made in China

Be the most trusted biotech company

2024-08-20

Henlius and Convalife Reach Global Strategic Cooperation on Neratinib
2024-08-08

First Patient Dosed of Phase 2 Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein in Combination with Serplulimab Plus HANBEITAI for the First-line Treatment of Locally Advanced or Metastatic Hepatocellular Carcinoma Patients
2024-08-07

Henlius to Release Latest Results of HANSIZHUANG and HANQUYOU at ESMO Congress 2024
2024-08-05

Henlius to Showcase Latest Results of Serplulimab in the Field of Lung Cancer at 2024 WCLC
2024-07-26

HANQUYOU launched for 4 years with international quality recognized worldwide
2024-07-11

Publication in Journal of Translational Medicine Highlighting Henlius' Dual HER2 Blockade Therapy Mechanism of Action
2024-07-10

Advances in HER2+ GC: Dual HER2 Blockade Therapy Presented on MED and ESMO GI
2024-07-04

Indonesian BPOM and KGbio Visit Henlius: Deepening Cooperation for Mutual Success
2024-07-02

Henlius Receives Approval in Japan for Phase 3 MRCT of Anti-PD-1 mAb Serplulimab Combo on First-Line mCRC

1
2
3
4
5
...
8